Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Phoenix & Scottsdale, AZ

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
608
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Phoenix & Scottsdale, AZ
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Phoenix & Scottsdale, AZ. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 577–588 of 608 matching trials with a site at Mayo Clinic, Phoenix & Scottsdale, AZ.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

NCT02603341
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Photon, Proton
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536
Site status not listed — check the official record
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Telisotuzumab vedotin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
56
States / cities
Mobile, Alabama • Phoenix, Arizona • Springdale, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting Not applicable Interventional

Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)

NCT06556654
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Reconstruction Surgery
Interventions
TRBR Device
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
22 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
20
States / cities
Scottsdale, Arizona • Tucson, Arizona • Irvine, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting No phase listed Observational

Intent of Surgery for IPMN

NCT07216521
Status at this site: Recruiting
View directory record Official record
Conditions
Intraductal Papillary Mucinous Neoplasm
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Timeline
2025
U.S. locations
8
States / cities
Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Voice Production for Adults With Age-related Dysphonia

NCT03702322
Site status not listed — check the official record
View directory record Official record
Conditions
Presbylarynx, Age-Related Dysphonia
Interventions
Voice therapy: respiratory, Voice therapy: glottal closure, Voice therapy: loud, Voice therapy: Semiocclusion
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting Phase 1 Interventional

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810
Status at this site: Recruiting
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelofibrosis, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Erdheim-Chester Disease, Refractory Follicular Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoplasmacytic Lymphoma, Refractory Myelodysplastic Syndrome, Refractory Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Refractory Waldenstrom Macroglobulinemia, Rosai-Dorfman-Destombes Disease, Primary Central Nervous System Lymphoma, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Erdheim-Chester Disease, Recurrent Fibroblastic Reticular Cell Sarcoma, Recurrent Histiocytic Sarcoma, Recurrent Interdigitating Dendritic Cell Sarcoma, Recurrent Rosai-Dorfman-Destombes Disease, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Fibroblastic Reticular Cell Sarcoma, Refractory Histiocytic Sarcoma, Refractory Interdigitating Dendritic Cell Sarcoma, Refractory Rosai-Dorfman-Destombes Disease
Interventions
Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting Not applicable Interventional

Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

NCT04565795
Status at this site: Recruiting
View directory record Official record
Conditions
Ureteral Diseases
Interventions
Uriprene® Degradable Temporary Ureteral Stent
Device
Lead sponsor
Adva-Tec
Industry
Eligibility
21 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting Phase 3 Interventional

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135
Status at this site: Recruiting
View directory record Official record
Conditions
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Interventions
Navtemadlin, Navtemadlin placebo, Ruxolitinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
58
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

NCT06245915
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Interventions
AB-2100
Biological
Lead sponsor
Arsenal Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Duarte, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

NCT06381141
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CLN-619
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting No phase listed Observational

PROMs After Pancreatectomy

NCT07173257
Status at this site: Recruiting
View directory record Official record
Conditions
Pancreas Neoplasms, Pancreatitis, Pancreatic Cyst
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting No phase listed Observational

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

NCT02523118
Status at this site: Recruiting
View directory record Official record
Conditions
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2051
U.S. locations
19
States / cities
Phoenix, Arizona • Rogers, Arkansas • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 23, 2026, 9:23 AM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Phoenix & Scottsdale, AZ as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.